Bhere, Deepak http://orcid.org/0000-0003-4142-5518
Choi, Sung Hugh
van de Donk, Pim
Hope, David http://orcid.org/0000-0001-5654-1744
Gortzak, Kiki
Kunnummal, Amina
Khalsa, Jasneet
Revai Lechtich, Esther http://orcid.org/0000-0002-3406-5959
Reinshagen, Clemens http://orcid.org/0000-0002-8524-4578
Leon, Victoria
Nissar, Nabil
Bi, Wenya Linda
Feng, Cheng
Li, Hongbin
Zhang, Yu Shrike http://orcid.org/0000-0002-0045-0808
Liang, Steven H. http://orcid.org/0000-0003-1413-6315
Vasdev, Neil
Essayed, Walid Ibn
Quevedo, Pablo Valdes
Golby, Alexandra
Banouni, Naima
Palagina, Anna
Abdi, Reza
Fury, Brian
Smirnakis, Stelios http://orcid.org/0000-0002-1929-2811
Lowe, Alarice
Reeve, Brock
Hiller, Arthur http://orcid.org/0000-0002-0104-9995
Chiocca, E. Antonio
Prestwich, Glenn
Wakimoto, Hiroaki http://orcid.org/0000-0001-8225-241X
Bauer, Gerhard
Shah, Khalid http://orcid.org/0000-0002-5474-0974
Article History
Received: 14 January 2021
Accepted: 3 May 2022
First Online: 19 May 2022
Change Date: 2 February 2024
Change Type: Clarification
Change Details: Editor's note: Readers are alerted that concerns have been raised regarding the reliability of the data presented in this article. Further editorial action will be taken if appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Competing interests
: K.S. owns equity in and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer. D.B. owns equity in and is a consultant at AMASA Therapeutics. K.S.’s and D.B.’s interests were reviewed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. The other authors declare that they have no competing interests.